Eupraxia Pharmaceuticals (EPRXF) Stock Price, News & Analysis

Company Overview

Eupraxia Pharmaceuticals, Inc. (OTCMKTS:EPRXF) is a clinical-stage biotechnology company advancing adeno-associated virus (AAV)-based gene therapies for rare inherited metabolic disorders. The firm’s research platform focuses on developing single-administration treatments designed to address the underlying genetic causes of enzyme deficiencies. Eupraxia’s approach leverages targeted gene delivery to restore or supplement critical metabolic functions in patients with life-threatening conditions.

The company’s lead pipeline candidates include EPRX-101 for Ornithine Transcarbamylase (OTC) deficiency and EPRX-102 for methylmalonic acidemia (MMA), both of which are in preclinical or IND-enabling stages. Eupraxia collaborates with contract research organizations and specialized manufacturing partners to support vector production, nonclinical toxicology studies and regulatory filings. The goal is to advance these programs into human trials, offering the potential for long-lasting therapeutic benefit from a single treatment.

Headquartered in Dallas, Texas, Eupraxia Pharmaceuticals targets patient populations worldwide afflicted by rare metabolic diseases. Its leadership team brings together experienced biotech executives and scientific experts in gene therapy development. By concentrating on orphan indications with high unmet need, Eupraxia aims to deliver innovative solutions that improve outcomes and quality of life for individuals with inherited enzyme deficiencies.

Key Stats

• Today's Range: C$6.33 to C$6.68
• 50-Day Range: C$5.81 to C$7.10
• 52-Week Range: C$2.93 to C$6.78
• Volume: 98,558 shs
• Average Volume: 7,410 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:EPRXF
• CIK: N/A
• Web: www.eupraxiapharma.com
• Phone: 250 590 3968
• Fax: N/A
• Employees: 21
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A